What is the significance of a markedly prolonged activated partial thromboplastin time (APTT) and how should it be evaluated?

Evaluation of High APTT Value

A markedly prolonged APTT with normal PT requires immediate mixing studies to differentiate between factor deficiency and inhibitors (lupus anticoagulant or factor VIII inhibitor), followed by specific factor assays and lupus anticoagulant testing, as this distinction is critical for preventing life-threatening bleeding or unnecessary anticoagulation. 1

Differential Diagnosis

A prolonged APTT with normal PT indicates three primary possibilities:

• Lupus anticoagulant (most common)
• Heparin therapy or other anticoagulants
• Coagulation factor deficiencies (factors VIII, IX, XI, XII) or acquired hemophilia A

Diagnostic Algorithm

Step 1: Mixing Studies (Time and Temperature Dependent)

Perform mixing studies immediately and after 2-hour incubation at 37°C 1:

• Mix patient plasma 1:1 with pooled normal plasma
• Test immediately and after 2 hours of incubation
• If aPTT corrects immediately and remains corrected: suggests factor deficiency
• If aPTT fails to correct or corrects initially but prolongs after 2-hour incubation: suggests inhibitor (FVIII autoantibodies are time and temperature-dependent) 1
• If aPTT fails to correct at both timepoints: suggests lupus anticoagulant (not time-dependent) 2

Critical caveat: Immediate correction does NOT exclude acquired hemophilia A if clinical presentation is suggestive of bleeding. Further investigation is mandatory regardless of mixing study results. 1

Step 2: Specific Factor Assays

Measure factors VIII, IX, XI, and XII levels in parallel with mixing studies 1:

• Isolated low FVIII: highly suggestive of acquired hemophilia A
• All intrinsic factors decreased: may represent in vitro artifact from FVIII inhibitor depleting substrate plasma
• Artifactually low factors with lupus anticoagulant: repeat assays at higher serial dilutions to attenuate inhibitor effect 1

Step 3: Lupus Anticoagulant Testing

Perform specific lupus anticoagulant tests using phospholipid-dependent assays 2:

• dRVVT (dilute Russell viper venom time) should be first test
• Sensitive aPTT (low phospholipids, silica activator) as second test
• Confirmatory testing: repeat with increased phospholipid concentration
• Lupus anticoagulants are NOT time-dependent, distinguishing them from FVIII inhibitors 1

Step 4: Bethesda Assay (if FVIII inhibitor suspected)

Quantify inhibitor titer if acquired hemophilia A is suspected 1:

• Report titer at dilution closest to 50% inhibition
• Inhibitor may not be initially apparent with low FVIII activity—re-screen after several days if suspicion remains
• Consider FVIII antibody ELISA in complex cases where both lupus anticoagulant and FVIII autoantibodies may coexist 1

Clinical Context Matters

If Bleeding Present:

This is a medical emergency with 9-31% mortality risk 1. Acquired hemophilia A must be ruled out urgently:

• Retroperitoneal, intracranial, gastrointestinal, or pulmonary bleeding requires immediate hemostatic treatment
• Fatal bleeding can occur up to 5 months after presentation if autoantibody not eliminated 1

If No Bleeding:

• Lupus anticoagulant is most likely (associated with thrombosis risk, not bleeding)
• Contact factor deficiencies (especially prekallikrein or factor XII) cause marked aPTT prolongation without bleeding risk 3
• Consider preanalytical issues and reagent sensitivity 4, 5

Common Pitfalls to Avoid

1. Do not assume correction on mixing excludes acquired hemophilia A—always perform specific factor assays in parallel 1

2. Do not forget the 2-hour incubation—FVIII inhibitors are time-dependent and may only manifest after incubation 1

3. Lupus anticoagulant and FVIII autoantibodies can coexist in the same patient—both must be tested 1

4. Heparin contamination must be excluded with anti-factor Xa assay or thrombin time 5, 6

5. Reagent sensitivity varies markedly—different aPTT reagents have different sensitivities to lupus anticoagulant and factor deficiencies 4, 6

Preanalytical Considerations

• Blood should be collected in 0.109 M sodium citrate (9:1 ratio)
• Double centrifugation required to ensure platelet-poor plasma (>2500g for 10 minutes) 2
• If testing delayed, freeze plasma quickly at -70°C and thaw at 37°C for 5 minutes before testing 2
• Anticoagulant therapy (especially DOACs) can interfere with testing—ideally test before starting or after adequate washout period 4